|
1) Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis [published correction appears in N Engl J Med. 2006; 354: 2200]. N Engl J Med. 2005; 353: 2462-76
|
|
|
|
2) Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008; 6: 1112-6
|
|
|
|
|
|
3) Yang Z, Wu Q, Wu K, et al. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2010; 31: 486-92
|
|
|
|
|
|
4) Colombel JF, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-95
|
|
|
|
|
|
5) Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009; 104: 2524-33
|
|
|
|
|
|
6) Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with inflixi-mab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009; 48: 386-8
|
|
|
|
|
|
7) Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled inflixi-mab maintenance: a randomized trial. Gastroenterology. 2008; 134: 1861-8
|
|
|
|
|
|
8) Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006; 130: 650-6
|
|
|
|
|
|
9) Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65
|
|
|
|
|
|
10) Schreiber S, Colombel JF, Bloomfield R, et al. PRECiSE 2 Study Investigators. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010; 105: 1574-82
|
|
|
|
|
|
11) Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimu-mab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146: 829-38
|
|
|
|
|
|
12) Regueiro M, Schraut W, Baidoo L, et al. Inflixi-mab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009; 136: 441-50
|
|
|
|
|